|
03 May 2019 |
Amgen And Syapse Enter Precision Medicine Collaboration In Oncology
|
|
02 May 2019 |
Transgene and AstraZeneca enter into a collaboration and exclusive license option agreement for innovative Invir.IOTM based armed oncolytic immunotherapies
|
|
01 May 2019 |
Tmunity and UC San Francisco Announce Exclusive License and Research Collaboration to Advance TCR T Cell Therapies for Pediatric Cancers
|
|
01 May 2019 |
AstraZeneca starts artificial intelligence collaboration to accelerate drug discovery
|
|
30 Apr 2019 |
Sandoz enters agreement for proposed trastuzumab biosimilar, currently in Phase III development, to treat selected HER2-positive cancer tumors
|
|
29 Apr 2019 |
Iktos Announces Research Collaboration with Janssen to Utilize Iktos’ Artificial Intelligence Technology to Increase Speed & Efficiency of Small Molecule Drug Discovery
|
|
29 Apr 2019 |
Calixar signs exclusive licensing agreement with Regeneron on undisclosed therapeutic target
|
|
25 Apr 2019 |
Daiichi Sankyo Selects Lead Candidate Built on Zymeworks’ Azymetric™ Bispecific Platform
|
|
25 Apr 2019 |
Salix Enters Into Exclusive License Agreement With Mitsubishi Tanabe Pharma To Develop And Commercialize Late Stage Investigational S1P Modulator For The Treatment Of Inflammatory Bowel Disease
|
|
24 Apr 2019 |
ADC Therapeutics and Adagene Announce License Agreement
|
|
23 Apr 2019 |
Lilly and Avidity Biosciences Announce Licensing and Research Collaboration
|
|
23 Apr 2019 |
Variant Pharmaceuticals Expands Development Focus Into $60+ Billion Anti-inflammatory Market with Worldwide License to Novel Inflammasome Inhibitor
|
|
23 Apr 2019 |
Fulcrum Therapeutics Acquires Global Rights to Losmapimod, a Potential Disease-Modifying Therapy for Facioscapulohumeral Muscular Dystrophy
|
|
18 Apr 2019 |
Arrakis Therapeutics Announces $75 Million Series B Financing to Advance a New Class of Small-Molecule Medicines Targeting RNA
|
|
17 Apr 2019 |
CASI Pharmaceuticals In-Licenses Exclusive Worldwide Rights to Novel Anti-CD38 Monoclonal Antibody Program From Black Belt Therapeutics
|
|
17 Apr 2019 |
RNA Therapeutics Startup Panorama Medicine Raises $3.7 Million to Accelerate Drug Discovery Using Genomics and Artificial Intelligence
|
|
17 Apr 2019 |
PureTech Health Announces Collaboration with Boehringer Ingelheim to Advance Immuno-oncology Product Candidates using its Lymphatic Targeting Platform
|
|
17 Apr 2019 |
Gilead and insitro Announce Strategic Collaboration to Discover and Develop Novel Therapies for Nonalcoholic Steatohepatitis
|
|
15 Apr 2019 |
Allele Biotechnology and SCM Lifescience Sign a Joint Research and Development Agreement to Develop iPSC-based Diabetes Treatment
|
|
12 Apr 2019 |
Gyroscope Therapeutics merges with Orbit Biomedical creating a leading retinal gene therapy company
|
|
12 Apr 2019 |
Ophthotech Obtains Exclusive Global License to AAV Gene Therapy Program for BEST1 Related Retinal Diseases
|
|
12 Apr 2019 |
Gilead Sciences and Novo Nordisk Announce Intent to Initiate a Clinical Collaboration in NASH
|
|
10 Apr 2019 |
Synaffix Announces License Agreement Worth up to $125 Million with Leading Chinese ADC Developer, Shanghai Miracogen
|
|
09 Apr 2019 |
BioAtla and BeiGene Form Worldwide Collaboration to Develop and Commercialize Novel Conditionally Active Biologic CTLA-4 Therapy
|
|
09 Apr 2019 |
Enesi Pharma and University of Oxford Collaborate to Target Plague With a Novel ImplaVax®-enabled Adenovirus-based Solid Dose Vaccine
|
